Brigimadlin vs Doxorubicin in Advanced Dedifferentiated Liposarcoma (DDLPS) - Brightline-1

In this episode of SARC Talk Journal Club, our panel discusses the Brightline-1 Phase II/III trial, evaluating brigimadlin (BI 907828) versus doxorubicin as first-line treatment for patients with advanced, MDM2-amplified dedifferentiated liposarcoma (DDLPS).The panel reviews the study design, progression-free survival, objective response rates, safety findings, and translational data surrounding this novel MDM2-p53 antagonist. We explore what the results tell us about targeting the MDM2-p53 pathway and the ongoing challenges of developing new treatments for advanced DDLPS.Join us for an expert discussion of this important sarcoma clinical trial and what the findings may mean for future liposarcoma research, targeted therapies, and clinical trial development.Abstract: https://pubmed.ncbi.nlm.nih.gov/42268294/